Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.
logous transplantation
Rituximab is a chimeric human/mouse monoclonal antibody directed against the CD20 antigen. It has shown activity as a single agent 1 and in combination with chemotherapy 2 in the treatment of B-cell non-Hodgkin's lymphoma (NHL). Rituximab is also increasingly used in the setting of stem cell transplantation. It can be used before stem cell harvest as a way of in vivo purging or after stem cell transplantation as an adjuvant therapy. Adverse effects are usually mild, and less than 1% of the patients developed grade 4 cytopenia when used as a single agent. 1 Recently, several cases of late-onset neutropenia have been described in relation to its utilisation. 3, 4 Reversible rituximab-related late-onset neutropenia tends to occur 2-6 months after rituximab therapy and can be associated with infectious complications. 4 In the postmarketing phase, the rate of lateonset neutropenia reported by Genentech (manufacturer of rituximab) was less than 0.02%. 3 Here, we report six cases of rituximab-related late-onset neutropenia after high-dose chemotherapy and autologous stem cell transplantation.
Patients and methods
The characteristics of patients with late-onset neutropenia are shown in Table 1 . All patients had diffuse large-cell NHL and they received ACVB (adriamycin, cyclophosphamide, vindesine and bleomycin) and high-dose chemotherapy as part of their first-line treatment. The ACVB regimen followed by stem cell transplantation represents the standard therapy in our department for patients with aggressive NHL and an age-adjusted IPI 41. 5 Rituximab was given at a dose of 325 mg/m 2 with each course of ACVB for three patients. In the other three patients, rituximab was given at a dose of 325 mg/m 2 for 4 consecutive weeks just before or after stem cell transplantation. The stem cell transplantation was well tolerated. The median dose of reinfused stem cells was 9.2 Â 10 6 CD34 þ / kg. The median duration of neutropenia after transplantation was 9 days.
Late-onset neutropenia developed 76 to 192 days after the completion of rituximab (median time after stem cell transplantation 114 days). The diagnosis was carried out because of complications in four patients and on routine blood count for the two other patients. The nadir of the neutrophil count was below 500 cell/mm 3 for each patient. The platelet count was over 125 Â 10 9 /l for every patient and haemoglobin levels were between 9 and 12 g/dl. Usual known causes of neutropenia, such as CMV infection, were excluded. A bone marrow aspiration was performed in five patients (patients 2-6). In four samples, bone marrow showed maturation arrest with the accumulation of promyelocytes and myelocytes. The last sample showed a hypoplastic bone marrow with no sign of impairment of granulopoiesis. Five out of six patients were hospitalised because of neutropenia-related complications (median time of hospital stay, 5 days). Only one patient (patient 5) had proven bacterial infection. Four of the five patients hospitalised received granulocyte colony-stimulating factor (G-CSF). They received a median number of three G-CSF injections. All patients recovered a normal neutrophil count with the disappearance of the infection and no patient experienced relapse.
Discussion
We report six cases of late-onset neutropenia occurring in patients treated with high-dose therapy and rituximab. These six patients represent 15% (5/39) of the patients treated with the same protocol (ACVB/stem cell transplantation and rituximab) in our department during a 4-year period. The characteristics of our cases with regard to the timing of development (2-6 months after rituximab), nadir neutrophil count (below 500 cell/mm 3 ) and resolution are in accord with the other cases described. 3, 4 For all these patients, no other cause of neutropenia could be found. All the patients treated with G-CSF responded promptly.
Chaiwatanatorn et al 4 were the first to establish a possible link between delayed-onset neutropenia and rituximab. They described seven cases of neutropenia occurring in patients treated with rituximab. For each of these cases, neutropenia developed 1-6 months after rituximab treatment. Nadir neutrophil count was under 500 cells/mm 3 . The median duration of grade 4 neutropenia was 9 days. No other cause of neutropenia was found, although all of these patients had received a considerable amount of myelotoxic agents in the past. This report was followed by another report by Voog et al. 3 They described eight cases of delayed-onset neutropenia. Each of their patients was treated with rituximab (median time to severe neutropenia 16 weeks). Four of these cases were associated with stem cell transplantation. All patients recovered normal neutrophil counts after a median time of 6 days.
Flinn et al 6 has also observed a high incidence of lateonset neutropenia in the setting of stem cell transplantation. They described six cases of neutropenia of uncertain aetiology in a series of 25 patients treated with rituximab before and after stem cell transplantation. At the time of publication, rituximab was not considered as a possible cause for those events. These patients developed transient severe (o500/mm 3 ) neutropenia after transplantation (median time 99.5 days). Neutropenia resolved in all cases. These characteristics are in agreement with the description of rituximab-related late-onset neutropenia.
Rituximab-related late-onset neutropenia is an exclusion diagnosis. The aetiology of this complication is not known. As opposed to other cases described, accumulated bone marrow toxicity cannot be implicated in our cases since rituximab was part of the initial treatment received by these patients. Direct cytotoxicity of rituximab is also improbable since CD20 is not expressed by the neutrophil or its precursors. A defect in B-cell reconstitution with immune dyscrasia caused by rituximab has been proposed by Chaiwatanatorn et al as a possible mechanism for lateonset neutropenia. The chronology and favourable outcome are in favour of an immune mechanism. Several immune disorders can be encountered after autologous transplantation. They may reflect an imbalance of T-cell subpopulation recovery in this setting. 7 Two cases of T-large granular lymphocyte (T-LGL)-mediated neutropenia after treatment with rituximab have also been described. 8 Papadaki et al observed a small population of T-LGL in the bone marrow of two patients treated with rituximab. This population, which was not detected before treatment with rituximab, was discovered at the time of neutropenia. This expanded population was implicated in the development of neutropenia even though its presence could not be explained. T-LGL is a known cause of neutropenia. The exact mechanism for neutropenia development in this context is not fully understood, although both Fas/Fas ligand-dependent and -independent mechanisms have been described. 9, 10 In conclusion, rituximab use is a potential cause of lateonset neutropenia after stem cell transplantation. Severe neutropenia combined with the immunosuppression of the post-transplantation period could predispose to serious infectious complications, although the patients in this series did not experience life-threatening events. The actual incidence of this complication is not known, nor the impact of stem cell transplantation on its development. Effort should be made to clarify its pathogenesis and identify patients at risk. In the mean time, since rituximab is increasingly used in stem cell transplantation protocol, patients should have blood count carried out on a regular basis for at least 6 months following transplantation. This will facilitate early intervention and potentially prevent harmful complications.
